Complete molecular remission in chronic myelogenous leukemia after imatinib therapy

N Engl J Med. 2002 Aug 15;347(7):539-40. doi: 10.1056/NEJM200208153470719.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Imatinib Mesylate
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Polymerase Chain Reaction
  • Pyrimidines / therapeutic use*
  • RNA, Messenger / analysis
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • RNA, Messenger
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl